/** Title: Granules India Q1 FY27: Strong cash flow, complex generics mix shift, and capacity ramp-up in focus */

Granules India Q1 FY27: Strong cash flow, complex generics mix shift, and capacity ramp-up in focus

Granules India opened FY27 with its strongest first quarter to date, supported by a sharper product mix and better cash conversion. Revenue for Q1 FY27 stood at INR 1,476.8 crore, up 22% year-on-year. EBITDA rose 37% to INR 338.9 crore, with EBITDA margin improving to 22.9%. Profit after tax increased 60% to INR 180 crore. Just as notable was the balance sheet movement: net debt to EBITDA improved to 0.07x and operating cash flow rose to INR 387.4 crore.

Management framed the quarter as evidence of a broader transition: Granules is positioning itself as a more complex and differentiated generics platform, rather than a pure scale and cost story. The headline operational proof point was in finished dosages, where the company stated that complex generics now account for 50% of the finished-dosage portfolio, up from 39% a year ago. This mix upgrade was repeatedly linked to structural margin improvement.

While the company acknowledged input cost pressures and supply chain volatility driven by geopolitical tensions in West Asia, it highlighted that opening inventory levels in the US helped keep Q1 gross margins largely insulated. Management also indicated it is pursuing calibrated pricing actions and cost pass-through mechanisms where possible to manage the next couple of quarters.

Financial performance and what drove it

Granules reported gross margin of 65.6% in Q1 FY27, up 74 basis points year-on-year. The expansion was attributed to a higher contribution from complex and higher value formulations. Manpower costs and R&D spend rose 26% and 30% year-on-year respectively, reflecting investments in talent and pipeline. R&D expenses were INR 88 crore, equal to 6.0% of sales.

The quarter also stood out for cash generation. The CFO attributed the strong operating cash flow primarily to disciplined working capital management, including a substantial reduction in receivables, and to moderated capex as the large Genome Valley investment has been completed.

Revenue mix: diversification improving, but US still dominant

By business segment, finished dosages remained the anchor at 74% of Q1 revenue. APIs contributed 13%, PFIs 9%, and CDMO 4%. Year-on-year growth was driven primarily by finished dosages and complex generics.

Geographically, North America accounted for 72% of Q1 revenue, Europe 16%, and Rest of World 12%. The quarter continued a multi-quarter trend of faster growth outside the US: Europe grew 51% year-on-year and Rest of World grew 56%. Management described this as planned growth, supported by demand from products filed earlier in Europe, spanning both API and finished dosage businesses.

Strategy watch: complex generics, Gagillapur, and Genome Valley ramp-up

Granules’ strategic narrative remains anchored around moving up the complexity curve. The investor presentation defined complex generics as products with high entry barriers driven by formulation complexity, API complexity, IP and bioequivalence strategies, compliance complexity, or drug-device or route-of-administration barriers. In Q1, management stated complex generics are now half of the finished-dosage portfolio, and it continues to spend in complex pipeline development.

Regulatory and quality readiness also remained a key theme. The presentation highlighted that GPI (Virginia) received a VAI-classified FDA EIR for its April 2026 inspection. It also noted that the Czech agency issued an EU GMP certificate for Genome Valley. Management emphasized it has undergone more than 330 customer and regulatory audits over the past two years without a single critical observation.

However, the overhang remains Gagillapur. Management said remediation work is essentially complete and that it met the FDA in January, with responses submitted on time and no concerns raised by the agency so far on adequacy or pace of corrective actions. Still, Gagillapur remains the only site without a clean EIR status in the company’s network, and new product approvals linked to that site are pending until reinspection and clearance. Management indicated that applications are ready to launch once clearance is obtained, and separately stated that about nine approvals are pending facility approval.

Genome Valley (also referenced as GLS) is the capacity lever for the next phase. The company stated that the 10 billion dosage facility is USFDA approved, with Rx product shipments started, and that it increases formulation capacity by around 40%. On the concall, management said utilization is currently low but expected to cross 50% by the end of FY27. It also described product extensions and alternate-site approvals as a way to improve supply resilience, especially given the dependence on Gagillapur for certain products.

Peptide CDMO: scaling plan, but quarter-to-quarter volatility is real

Peptide CDMO remains a central long-term growth platform, built around the acquisition of Senn Chemicals in April 2025. The company disclosed that peptide CDMO had an EBITDA loss of INR 12.4 crore in Q1 FY27, compared to positive EBITDA in Q4 FY26, which it attributed to project milestone mix and the inherent variability of a project-driven business.

Management’s guidance for FY27 on peptides was specific in one key way: it aims to deliver a PAT-positive performance for the peptide business on an annual basis, while accepting quarter-to-quarter variability. It also shared medium-term validation metrics: a milestone of USD 50 million revenue with 30% plus EBITDA margin, and customer wins that can scale to around USD 10 million annual potential, as a proof point in the middle of a five-year growth journey.

Operationally, management discussed upgrades at the Zurich site, including additional solid phase reactors, purification columns, and lyophilization capacity. It also said land has been earmarked for a peptide facility at Vizag in India. In response to a question on India investments, management provided initial estimates: around INR 100 crore for intermediate side investment and about INR 200 crore for API side investment, with the caveat that these are initial estimates and may not be fully realized in the first year.

Key investor takeaways

Granules’ Q1 FY27 performance combined strong growth with visible improvements in cash generation and leverage. The company’s emphasis on complex generics is now showing up in reported mix and margins, while investments in R&D and compliance digitalization point to a longer runway.

At the same time, investors will continue to track three operational variables closely. First, the timing of regulatory clearance at Gagillapur, given the backlog of approvals and launches tied to that site. Second, the pace of Genome Valley ramp-up and how quickly it becomes a meaningful alternate manufacturing base. Third, the path to more stable profitability in peptide CDMO, where management has set an annual PAT-positive target for FY27 but acknowledged the lumpiness of the business.

On guidance, management reiterated FY27 capex guidance of INR 600 crore and indicated EBITDA margins are expected to remain in the 22% to 23% range, with R&D spend expected around 5.5% to 6% of sales. If execution on regulatory closure and capacity ramp-up stays on track, the quarter’s theme of portfolio upgrade backed by cash flow could carry through the year.